Detalhe da pesquisa
1.
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Clin Cancer Res
; 24(1): 62-72, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061643
2.
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
JAMA Oncol
; 4(11): 1583-1588, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29931076
3.
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Clin Cancer Res
; 23(10): 2442-2450, 2017 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27810904
4.
Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
Clin Cancer Res
; 21(24): 5445-52, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26152744